Literature DB >> 15043161

Anti-cowpox virus activities of certain adenosine analogs, arabinofuranosyl nucleosides, and 2'-fluoro-arabinofuranosyl nucleosides.

Donald F Smee1, Robert W Sidwell.   

Abstract

Nucleoside analogs were investigated for their potential to inhibit cowpox virus (a surrogate for variola and monkeypox viruses) in cell culture and in lethal respiratory infections in mice. Cell culture antiviral activity was determined by plaque reduction assays, with cytotoxicity determined by cell proliferation assays. Selectivity indices (SI's, 50% cytotoxic concentration divided by 50% virus-inhibitory concentration) were determined for 15 compounds. Three arabinofuranosyl (Ara) nucleosides showed activity in mouse mammary tumor (C127I) cells: guanine (Ara-G), thymine (Ara-T), and adenine (Ara-A) with SI's of 113, 61, and 95, respectively. The 2'-fluoro-Ara nucleosides of 5-F-cytosine (FIAC), 5-methyluracil (FMAU), and 5-iodouracil (FIAU) exhibited SI's of 148, 77, and 29, respectively. Other potent compounds included cidofovir (a positive control) and 3'-O-methyladenosine, with SI values of 164 and 56, respectively. In general, assays performed in African green monkey kidney (Vero) cells produced lower SI's than in C127I cells, except for 5-iodo-2'-deoxyuridine (IDU) which had an SI of > 71 in Vero cells and 3.1 in C127I cells. Intranasal infection of mice with cowpox virus was followed a day later by twice daily intraperitoneal treatment with compounds for 5 days. Ara-A was active at 300 mg/kg/day (40% survival), FMAU at 100 mg/kg/day (70% survival), and cidofovir (given for 1 day only) at 100 mg/kg (80-100% survival). None of the other compounds, including IDU, prevented death nor delayed the time to death. Cidofovir had the best potential for treating orthopoxvirus infections of those tested.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15043161     DOI: 10.1081/ncn-120028334

Source DB:  PubMed          Journal:  Nucleosides Nucleotides Nucleic Acids        ISSN: 1525-7770            Impact factor:   1.381


  8 in total

1.  Orthopoxvirus inhibitors that are active in animal models: an update from 2008 to 2012.

Authors:  Donald F Smee
Journal:  Future Virol       Date:  2013-09       Impact factor: 1.831

Review 2.  Orthopoxvirus targets for the development of antiviral therapies.

Authors:  Mark N Prichard; Earl R Kern
Journal:  Curr Drug Targets Infect Disord       Date:  2005-03

3.  Vaccinia virus A35R inhibits MHC class II antigen presentation.

Authors:  Kristina E Rehm; Ramsey F Connor; Gwendolyn J B Jones; Kenneth Yimbu; Rachel L Roper
Journal:  Virology       Date:  2009-12-02       Impact factor: 3.616

4.  Design and synthesis of vidarabine prodrugs as antiviral agents.

Authors:  Wei Shen; Jae-Seung Kim; Phillip E Kish; Jie Zhang; Stefanie Mitchell; Brian G Gentry; Julie M Breitenbach; John C Drach; John Hilfinger
Journal:  Bioorg Med Chem Lett       Date:  2008-12-10       Impact factor: 2.823

5.  Synthesis of N6 ,N6-Dialkyl Adenine Nucleosides With In Situ Formed Hexaalkylphosphorus Triamides.

Authors:  Mahesh K Lakshman; Asad Choudhury; Suyeal Bae; Eliezer Rochttis; Padmanava Pradhan; Amit Kumar
Journal:  European J Org Chem       Date:  2009-01-01

6.  Activities of certain 5-substituted 4'-thiopyrimidine nucleosides against orthopoxvirus infections.

Authors:  Earl R Kern; Mark N Prichard; Debra C Quenelle; Kathy A Keith; Kamal N Tiwari; Joseph A Maddry; John A Secrist
Journal:  Antimicrob Agents Chemother       Date:  2008-11-24       Impact factor: 5.191

7.  Antiviral Activity of 4'-thioIDU and Thymidine Analogs against Orthopoxviruses.

Authors:  Mark N Prichard; Earl R Kern
Journal:  Viruses       Date:  2010-09-16       Impact factor: 5.818

8.  The chemoenzymatic synthesis of clofarabine and related 2'-deoxyfluoroarabinosyl nucleosides: the electronic and stereochemical factors determining substrate recognition by E. coli nucleoside phosphorylases.

Authors:  Ilja V Fateev; Konstantin V Antonov; Irina D Konstantinova; Tatyana I Muravyova; Frank Seela; Roman S Esipov; Anatoly I Miroshnikov; Igor A Mikhailopulo
Journal:  Beilstein J Org Chem       Date:  2014-07-22       Impact factor: 2.883

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.